Navigation Links
Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
Date:4/19/2012

pean Association of the Study of the Liver (EASL 2012) in Barcelona, Spain (Abstract #101). These results supplement the abstract findings highlighted today during an official EASL press conference.

"We are looking forward to the final results from this study, that we hope will be a significant step towards an interferon-free future for patients with HCV," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We are committed to the millions of people around the world who are chronically infected with HCV. Through our clinical trial program HCVerso™, we are working with experts worldwide to ask the difficult questions that remain in HCV to find answers to the challenges that these patients face."

Planning of the interferon-free Phase 3 clinical trial program is underway.

SOUND-C2 Pre-Specified Interim AnalysisIn this open-label Phase 2b study, 362 treatment-naive GT1 HCV patients were randomized into five interferon-free treatment groups, each with 120 mg BI 201335 QD, but with different dosing of BI 207127 and treatment durations. The randomization was stratified by HCV genotype (1a or 1b) and patient IL-28B genotype, with 41 percent of patients being GT1a and 75 percent being IL-28B CT or TT.SOUND-C2 Trial Design and Interim ResultsBI 201335

BI 207127

RBV

Treatment
Duration

SVR12
n (%)A

N=81

120 mg QD

600 mg TID

Y

16 wks

48 (59%)N=80

120 mg QD

600 mg TID

Y

28 wks

49 (61%)C

N=77

120 mg QD

600 mg TID

Y

40 wks

N/A*D

N=78

120 mg QD

600 mg BID

Y

28 wks

53 (68%)E

N=46

120 mg QD

600 mg TID

N

28 wks

18 (39%)* SVR12 data for the 40 week arm of SOUND-C2 is n
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
2. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
3. Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
4. QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
5. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
6. UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
7. Bionovos Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™
8. Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
9. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
10. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
11. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the ... Lilly and Company (NYSE: LLY ), Nektar Therapeutics ... ), and Novartis AG (NYSE: NVS ). Free ... http://investor-edge.com/register . On Friday, December 12, 2014, the ... Industrial Average lost 1.79%, to finish the day at 17,280.83, ...
(Date:12/15/2014)... and BOSTON , December ... leading GPCR structure-guided drug discovery and development company, is ... in the United States relating ... these patents in the US significantly strengthens the global ... major pharmaceutical markets. The suite of patents ...
(Date:12/13/2014)... , Dec. 12, 2014 HudsonAlpha Institute ... HiSeq X Ten sequencing system manufactured by Illumina, ... to produce and analyze genomic data faster and ... the Institute,s commitment to research programs for genomics ... X Ten provides unprecedented capacity, speed and accuracy ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... 4 NovaRx Corporation announced today the appointment of ... and Chief Operating Officer. Dr. Russell brings to ... discovery and a long history of success driving innovation ... experience leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... - Tasigna front-line data demonstrating potential in newly diagnosed patients with ... sessions at ASH , , - ... by significantly reducing toxic iron that can damage key organs , ... major independent breast cancer trial at SABCS to report on optimal ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Emergo Group, ... in 26 countries in North and South America, Europe, ... responses from industry participants for its 2015 Medical Device ... order to identify upcoming business and market trends as ... , The survey targets areas including:, , ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Kenmode Precision ... the firm as Director of Quality Assurance. He ... quality systems, processes and certifications for manufacturers in the ... posts of Corporate Quality Manager at Sonoco Products Company ... at NetCom, Inc., and Quality Assurance Manager for Prince ...
(Date:12/15/2014)... Metal drilling machines have ... This score indicates that neither buyers nor suppliers have ... have been raising the price of metal drilling machines ... rising demand,” according to IBISWorld business research analyst, Jeffrey ... During the past three years, high price driver volatility ...
Breaking Medicine News(10 mins):Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 3
... to excess days off, poor-quality output, study finds , , ... attention deficit hyperactivity disorder (ADHD) miss, on average, more ... to a new global reckoning of the problem. , ... worldwide have ADHD, according to survey data from the ...
... Neck, leg sites similar, but jugular should be choice for ... News) -- There,s little overall difference in infection risk if ... or an upper leg vein in critically ill patients, French ... is less likely to cause infection than the leg catheter. ...
... is not a phrase normally used to describe a ... Tel Aviv University, the chemical industry is a step ... from the School of Chemistry at Tel Aviv University ... certain steps of a complicated chain of chemical reactions ...
... With many Americans eagerly,awaiting some extra cash in their ... time to make an investment in your health. As ... Association and its,3,000 members urge you to invest your ... "What,s more important than investing in your health?" said ...
... Introduces EveryKid(TM), An Organic First For Children,s ... ... food,chemical-free nutrition is ideal to a child,s healthy growth and,development, parents ... of chemical vitamin,isolates. But today, New Chapter -- the leading producer ...
... explain why some nonsmokers contract the disease, study says , , ... increases the risk of lung cancer, even in nonsmokers, researchers ... alpha1-antitrypsin gene double someones risk of developing lung cancer, regardless ... explain why some nonsmokers develop the disease, said study author ...
Cached Medicine News:Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 2Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 3Health News:Dialysis Catheter Placement Makes Little Difference in Infection Risk 2Health News:1 small step for a lab science, 1 green leap for mankind 2Health News:Invest in Your Future With a Spa Visit Today 2Health News:Invest in Your Future With a Spa Visit Today 3Health News:Finally ... A Pure and Perfect Multi-Vitamin for Every Kid 2Health News:Finally ... A Pure and Perfect Multi-Vitamin for Every Kid 3Health News:Common Genetic Variant Tied to Lung Cancer Risk 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 3
Inquire...
Inquire...
Inquire...
... range of 18 Ophthalmic frames created ... producted to the very hightest quality. ... lightweight Titanium and Beta Titanium models, ... of beautifully formed and innovative designs ...
Medicine Products: